Reinier de Graaf Groep

The Cardiology department at Reinier de Graaf Groep is dedicated to advancing care for patients with atherosclerotic cardiovascular disease, atrial fibrillation, and related vascular conditions. Ongoing studies aim to test innovative lipid‑lowering therapies, evaluate safer anticoagulation options, and assess novel agents that target high‑risk heart and stroke outcomes.

• Emerging RNA‑based lipid‑modifying treatments
• Next‑generation antithrombotic strategies
• Integrated risk‑reduction programs for primary prevention
• Biomarker‑driven personalization of cardiovascular therapy

The site currently supports 17 active trials with 33 investigators, reflecting a strong focus on cardiovascular innovation.

Research at the hospital explores solutions for unexplained subfertility and improves outcomes for women undergoing assisted reproduction. Studies investigate hormonal support regimens and cost‑effective adjuncts to increase live‑birth rates, while also evaluating preventive strategies for reproductive tract lesions.

• Hormonal optimization in intra‑uterine insemination
• Non‑invasive diagnostics for early uterine pathology
• Vaccination approaches to reduce vulvar intraepithelial lesions

These initiatives complement the broader clinical portfolio, contributing to the 17 trials conducted at the site.

The oncology focus includes trials for breast cancer, colon and gastric malignancies, prostate cancer, and lymphomas. Efforts are directed toward evaluating adjuvant endocrine therapies, assessing the impact of low‑dose aspirin on cancer survival, and testing targeted agents that may improve disease‑free survival after standard treatment.

• Adjuvant endocrine therapy versus standard care in early breast cancer
• Low‑dose aspirin as a preventive measure in colorectal cancer recurrence
• Immunotherapy consolidation for high‑risk diffuse large B‑cell lymphoma
• Novel radioligand therapy for metastatic prostate cancer

The oncology program benefits from the multidisciplinary expertise of the 33 investigators across 17 active studies.

Studies targeting metabolic health address obesity, overweight status, and severe hypertriglyceridemia. Clinical work evaluates agents that lower triglyceride levels, reduce lipoprotein(a), and support weight management, with the goal of decreasing cardiovascular risk in metabolically challenged patients.

• Triglyceride‑lowering therapies for high‑risk ASCVD patients
• Lipoprotein(a) reduction strategies using antisense technology
• Integrated lifestyle and pharmacologic interventions for obesity

These metabolic investigations form a key component of the site’s 17 clinical trials, driven by a team of 33 investigators.

While the primary focus remains cardiovascular and oncologic research, the centre also supports exploratory work on viral infections that intersect with chronic disease management. Efforts include assessing the impact of viral triggers on cardiovascular events and evaluating vaccination strategies for virus‑related malignancies.

• Influence of chronic viral infections on atherosclerosis progression
• Preventive vaccination in patients with virus‑associated cancers
• Antiviral adjuncts to reduce cardiovascular complications

This niche area adds breadth to the overall research portfolio encompassing 17 trials and 33 investigators.

Investigations under this theme examine normal and altered physiological processes of the reproductive and urinary systems. Projects aim to refine diagnostic markers for early detection of urinary disorders and to understand hormonal cycles that affect fertility outcomes.

• Biomarkers for early identification of urinary tract dysfunction
• Hormonal profiling to predict successful assisted reproduction
• Non‑invasive imaging techniques for reproductive health assessment

These studies complement the broader clinical trial landscape at Reinier de Graaf Groep, contributing to the total of 17 active trials overseen by 33 investigators.